- Home
- ZLAB vs PLUS Comparison
ZLAB vs PLUS Comparison
Compare ZLAB & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- PLUS
- Stock Information
- Founded
- ZLAB 2013
- PLUS 1990
- Country
- ZLAB China
- PLUS United States
- Employees
- ZLAB N/A
- PLUS N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- PLUS Retail: Computer Software & Peripheral Equipment
- Sector
- ZLAB Health Care
- PLUS Technology
- Exchange
- ZLAB Nasdaq
- PLUS Nasdaq
- Market Cap
- ZLAB 3.6B
- PLUS 1.7B
- IPO Year
- ZLAB 2017
- PLUS 1996
- Fundamental
- Price
- ZLAB $36.40
- PLUS $72.46
- Analyst Decision
- ZLAB Buy
- PLUS
- Analyst Count
- ZLAB 5
- PLUS 0
- Target Price
- ZLAB $54.28
- PLUS N/A
- AVG Volume (30 Days)
- ZLAB 886.5K
- PLUS 226.6K
- Earning Date
- ZLAB 08-05-2025
- PLUS 08-05-2025
- Dividend Yield
- ZLAB N/A
- PLUS N/A
- EPS Growth
- ZLAB N/A
- PLUS N/A
- EPS
- ZLAB N/A
- PLUS 4.05
- Revenue
- ZLAB $418,326,000.00
- PLUS $2,068,789,000.00
- Revenue This Year
- ZLAB $44.07
- PLUS $3.88
- Revenue Next Year
- ZLAB $49.13
- PLUS $2.84
- P/E Ratio
- ZLAB N/A
- PLUS $17.89
- Revenue Growth
- ZLAB 43.72
- PLUS N/A
- 52 Week Low
- ZLAB $16.01
- PLUS $53.83
- 52 Week High
- ZLAB $44.34
- PLUS $106.98
- Technical
- Relative Strength Index (RSI)
- ZLAB 52.67
- PLUS 57.62
- Support Level
- ZLAB $34.79
- PLUS $70.16
- Resistance Level
- ZLAB $36.73
- PLUS $75.80
- Average True Range (ATR)
- ZLAB 1.23
- PLUS 2.08
- MACD
- ZLAB -0.46
- PLUS -0.26
- Stochastic Oscillator
- ZLAB 25.91
- PLUS 57.18
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About PLUS ePlus inc.
ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.